Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says

Executive Summary

Mylan CEO Heather Bresch may have done her company little favors by arguing it couldn't reduce EpiPen's price, with one analyst telling the firm it needs to get a little contrition and acknowledge its decision to raise the medicine's cost.


Related Content

Clinton's Plan To Tame 'Unjustified' Drug Prices: Who's At Risk?
Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Move Over Turing, Valeant – Mylan Next Target For Price Scrutiny


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts